Pune Magazine

“Rheumatoid Arthritis Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the

technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.

• Rheumatoid Arthritis companies working in the treatment market are Abbvie, Eli Lilly and Company/Incyte, Taiho Pharmaceutical, Rise Therapeutics, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others, are developing therapies for the Rheumatoid Arthritis treatment

• Emerging Rheumatoid Arthritis therapies in the different phases of clinical trials are- Upadacitinib (RINVOQ), Barticinib (OLUMIANT), TAS5315, R-2487, RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.

• In October 2026, Artiva Biotherapeutics announced upcoming clinical data presentations for AlloNK (AB-101), an investigational allogeneic natural killer (NK) cell therapy being developed for autoimmune diseases. The company reported plans to initiate a Phase III registrational trial in refractory rheumatoid arthritis in the second half of 2026. AlloNK is being evaluated with rituximab to support B-cell depletion. The candidate remains investigational for RA.

• In October 2026, Celltrion reported U.S. clearance to initiate a Phase III clinical trial evaluating Zymfentra (subcutaneous infliximab, CT-P13 SC) for rheumatoid arthritis. The development program aims to expand the therapy’s use beyond its existing inflammatory bowel disease indications. This is a clinical-trial regulatory development, not an FDA marketing approval for RA.

• In September 2026, SynAct Pharma reported further analysis of its Phase IIb ADVANCE study of resomelagon in treatment-naïve patients with highly active rheumatoid arthritis. The post-hoc analysis supported findings from the earlier EXPAND study and informed plans for Phase III development. The company said it planned to discuss the proposed Phase III trial design with the FDA in Q4 2026.

• In August 2026, Spyre Therapeutics announced topline results from the RA substudy of its Phase II SKYWAY trial evaluating SPY072, an investigational TL1A-targeting antibody. Both evaluated doses showed statistically significant benefits over placebo on one or more endpoints, including DAS28-CRP and ACR20. However, the magnitude of effect did not meet the company’s internal threshold for prioritizing SPY072 as an RA monotherapy. The findings supported proof of mechanism but did not establish an FDA-approved treatment.

• In July 2026, Precision immunology company Scipher Medicine has announced its merger with Chemomab Therapeutics, following the identification of the Israeli biotech’s liver disease candidate as a strong strategic fit with Scipher’s expertise. The combined company will continue operating under the Scipher name while utilizing Chemomab’s Nasdaq listing, with the stock ticker changing to “SCIP.” The merged entity will primarily focus on advancing nebokitug, Chemomab’s anti-CCL24 antibody, which is slated to enter a Phase II clinical trial for the treatment of rheumatoid arthritis.

• In July 2026, Emerging and investigational therapies for rheumatoid arthritis are expanding the treatment landscape, with Janus kinase (JAK) inhibitors and Bruton’s tyrosine kinase (BTK) inhibitors showing significant potential to reduce inflammation and improve disease management. In addition, innovative approaches such as vagus nerve stimulation are under investigation as potential therapies to enhance clinical outcomes and improve patients’ quality of life.

• In June 2026, Generic drug manufacturer Aurobindo Pharma has secured final approval from the U.S. Food and Drug Administration (FDA) for its Tofacitinib Tablets USP, available in 5 mg and 10 mg strengths. The approved product has been confirmed as bioequivalent and therapeutically equivalent to Xeljanz Tablets (5 mg and 10 mg), marketed by PF Prism C.V. Manufacturing will take place at APL Healthcare’s Unit IV, a subsidiary of Aurobindo Pharma, with commercial launch planned immediately following the approval.

• In June 2026, According to the latest guidance from the European Alliance of Associations for Rheumatology (EULAR), the increasing availability of biosimilar disease-modifying antirheumatic drugs (DMARDs) and the introduction of generic Janus kinase inhibitors (JAK inhibitors) have significantly influenced recommendations on treatment sequencing for patients with rheumatoid arthritis (RA). Published in the Annals of the Rheumatic Diseases, the 2025 EULAR recommendations for managing RA with synthetic and biologic DMARDs represent the most streamlined version of the guidance so far, reducing the number of recommendations from 11 to 9. The update was undertaken three years after the 2022 revision to incorporate new evidence from strategic clinical trials and emerging safety data related to JAK inhibitors, prompting a reevaluation of the current therapeutic approach.

• In January 2026, SetPoint Medical, a biotechnology company focused on innovative treatments for chronic autoimmune conditions, announced the publication of results from its RESET-RA study in Nature Medicine. This pivotal, double-blind, randomized, sham-controlled trial assessed the safety and effectiveness of the SetPoint System, an implantable neuroimmune modulation device that targets the vagus nerve. The therapy is designed for adults with moderate to severe rheumatoid arthritis (RA) who have an inadequate response to, or are unable to tolerate, currently available advanced RA treatments, including biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs).

• In September 2025, Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for children aged six years and older weighing at least 40 kg with moderate to severe plaque psoriasis (PsO) who are eligible for systemic therapy or phototherapy, as well as for active psoriatic arthritis (PsA). This approval marks TREMFYA® as the first and only IL-23 inhibitor authorized for these pediatric indications, expanding upon its prior FDA approvals for adults with moderate to severe plaque PsO in 2017 and active PsA in 2020.

• In April 2025, The European Medicines Agency (EMA) granted approval for Cullinan Therapeutics’ clinical trial application of CLN-978, a potential treatment for rheumatoid arthritis (RA). This Phase I open-label study will enroll patients with active, treatment-resistant RA, as defined by the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria. The trial is designed to evaluate the drug’s pharmacokinetics, pharmacodynamics, safety profile, and its effect on disease activity.

• In February 2025, AnaptysBio’s Phase IIb trial evaluating rosinilimab for rheumatoid arthritis (RA) has delivered promising results, with some patients achieving the highest recorded response rates by week 14. Remarkably, 69% of participants attained low disease activity. The U.S.-based company presented findings from its randomized RENOIR trial (NCT06041269), which assessed the safety and tolerability of rosinilimab in moderate-to-severe RA patients previously treated with conventional disease-modifying drugs. The study successfully met its primary endpoint, demonstrating a statistically significant improvement in DAS28-CRP scores compared to placebo, reinforcing rosinilimab’s potential as an effective RA treatment.

Rheumatoid Arthritis Overview

Rheumatoid Arthritis (RA) is a chronic autoimmune disorder in which the immune system mistakenly attacks the joints, causing inflammation, pain, stiffness, and swelling. Over time, it can lead to joint damage, deformities, and reduced mobility. RA can also affect other organs, including the heart, lungs, and eyes. Early diagnosis and treatment are essential to manage symptoms, slow disease progression, and improve quality of life.

Explore the latest Rheumatoid Arthritis pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Rheumatoid Arthritis Clinical Trials

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:

• Upadacitinib (RINVOQ): Abbvie

• Barticinib (OLUMIANT): Eli Lilly and Company/Incyte

• TAS5315: Taiho Pharmaceutical

• R-2487: Rise Therapeutics

• OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation

• RINVOQ (upadacitinib): AbbVie

• Rabeximod (Rob 803): Cyxone

• Imvotamab: IGM Biosciences

• Sarilumab (Kevzara): Regeneron/Sanofi

• Baricitinib: Eli Lilly and Company

• Certolizumab pegol: UCB BIOSCIENCES GmbH

• Upadacitinib: AbbVie

• Tofacitinib: Pfizer

• Sarilumab SAR153191 (REGN88): Sanofi

• GenaKumab: Changchun GeneScience Pharma

• AIN457: Novartis

• Etanercept: Istituto Giannina Gaslini

Rheumatoid Arthritis Route of Administration

Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Rheumatoid Arthritis Molecule Type

Rheumatoid Arthritis Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Rheumatoid Arthritis Pipeline Therapeutics Assessment

• Rheumatoid Arthritis Assessment by Product Type

• Rheumatoid Arthritis By Stage and Product Type

• Rheumatoid Arthritis Assessment by Route of Administration

• Rheumatoid Arthritis By Stage and Route of Administration

• Rheumatoid Arthritis Assessment by Molecule Type

• Rheumatoid Arthritis by Stage and Molecule Type

DelveInsight’s Rheumatoid Arthritis Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies

Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:

Key companies developing therapies for Rheumatoid Arthritis are – Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., and others.

Rheumatoid Arthritis Pipeline Analysis:

The Rheumatoid Arthritis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.

• Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies

Rheumatoid Arthritis Pipeline Market Drivers

• Rising prevalence of arthritis and other joint disorders, rising combinational therapy of biologics for the treatment of Rheumatoid Arthritis, rich emerging pipeline, acceptance of biosimilars for treatment of Rheumatoid Arthritis are some of the important factors that are fueling the Rheumatoid Arthritis Market.

Rheumatoid Arthritis Pipeline Market Barriers

• However, high cost of biologics, low adherence to the drugs, lack of daily assessment of RA • Delay in RA diagnosis and other factors are creating obstacles in the Rheumatoid Arthritis Market growth.

Scope of Rheumatoid Arthritis Pipeline Drug Insight

• Coverage: Global

• Key Rheumatoid Arthritis Companies: Abbvie, Eli Lilly and Company/Incyte, Taiho Pharmaceutical, Rise Therapeutics, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others

• Key Rheumatoid Arthritis Therapies: Upadacitinib (RINVOQ), Barticinib (OLUMIANT), TAS5315, R-2487, RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others

• Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies

• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers

Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials

Table of Contents

1. Rheumatoid Arthritis Report Introduction

2. Rheumatoid Arthritis Executive Summary

3. Rheumatoid Arthritis Overview

4. Rheumatoid Arthritis- Analytical Perspective In-depth Commercial Assessment

5. Rheumatoid Arthritis Pipeline Therapeutics

6. Rheumatoid Arthritis Late Stage Products (Phase II/III)

7. Rheumatoid Arthritis Mid Stage Products (Phase II)

8. Rheumatoid Arthritis Early Stage Products (Phase I)

9. Rheumatoid Arthritis Preclinical Stage Products

10. Rheumatoid Arthritis Therapeutics Assessment

11. Rheumatoid Arthritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Rheumatoid Arthritis Key Companies

14. Rheumatoid Arthritis Key Products

15. Rheumatoid Arthritis Unmet Needs

16 . Rheumatoid Arthritis Market Drivers and Barriers

17. Rheumatoid Arthritis Future Perspectives and Conclusion

18. Rheumatoid Arthritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services